Guggenheim Cuts Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $38.00

Olema Pharmaceuticals (NASDAQ:OLMA) had its target price cut by Guggenheim from $40.00 to $38.00 in a research note released on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other research firms have also recently issued reports on OLMA. HC Wainwright cut their target price on shares of Olema Pharmaceuticals from $45.00 to $38.00 and set a “buy” rating for the company in a research note on Monday, March 9th. UBS Group initiated coverage on shares of Olema Pharmaceuticals in a research note on Wednesday, January 7th. They issued a “buy” rating and a $45.00 price target on the stock. JPMorgan Chase & Co. raised their price objective on shares of Olema Pharmaceuticals from $29.00 to $32.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 18th. Piper Sandler started coverage on Olema Pharmaceuticals in a report on Wednesday, January 7th. They set an “overweight” rating and a $40.00 price objective for the company. Finally, TD Cowen reiterated a “buy” rating on shares of Olema Pharmaceuticals in a research note on Monday, March 9th. Eleven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $44.40.

Olema Pharmaceuticals Stock Up 2.7%

OLMA stock opened at $14.96 on Tuesday. Olema Pharmaceuticals has a 1-year low of $2.86 and a 1-year high of $36.26. The business’s 50 day simple moving average is $23.35 and its 200 day simple moving average is $18.67. The company has a current ratio of 9.95, a quick ratio of 8.03 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $1.03 billion, a PE ratio of -8.04 and a beta of 1.92.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its quarterly earnings results on Monday, March 16th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.01. As a group, research analysts anticipate that Olema Pharmaceuticals will post -2.33 EPS for the current year.

Insiders Place Their Bets

In other Olema Pharmaceuticals news, insider David C. Myles sold 50,000 shares of the stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $27.60, for a total transaction of $1,380,000.00. Following the transaction, the insider owned 542,761 shares in the company, valued at $14,980,203.60. This represents a 8.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Shawnte Mitchell sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $24.25, for a total transaction of $606,250.00. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 419,701 shares of company stock worth $11,603,868. 16.36% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Olema Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in OLMA. Titleist Asset Management LLC bought a new stake in shares of Olema Pharmaceuticals during the 2nd quarter valued at $64,000. Diadema Partners LP increased its position in shares of Olema Pharmaceuticals by 153.7% in the second quarter. Diadema Partners LP now owns 253,657 shares of the company’s stock worth $1,081,000 after purchasing an additional 153,657 shares during the period. Candriam S.C.A. increased its position in shares of Olema Pharmaceuticals by 46.9% in the third quarter. Candriam S.C.A. now owns 1,249,727 shares of the company’s stock worth $12,235,000 after purchasing an additional 399,273 shares during the period. Birchview Capital LP acquired a new position in Olema Pharmaceuticals in the second quarter valued at about $571,000. Finally, Kingdon Capital Management L.L.C. acquired a new position in Olema Pharmaceuticals in the third quarter valued at about $8,361,000. Institutional investors own 91.78% of the company’s stock.

Key Stories Impacting Olema Pharmaceuticals

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Positive Sentiment: Jefferies initiated coverage with a “Buy” and $40 price target (large upside vs. current levels), giving fresh institutional endorsement that can attract buyers. Jefferies Initiates Coverage – Benzinga
• Positive Sentiment: JPMorgan raised its price target to $58 and kept an “Overweight” stance — a high-profile upward revision that can drive momentum and re-rate expectations. JPMorgan Raises Price Target – Benzinga
• Positive Sentiment: HC Wainwright lifted EPS estimates across 2026–2030 and reiterated a “Buy” with a $38 target, signaling analyst confidence in improving fundamentals over the medium term. HC Wainwright Estimate Raises – MarketBeat
• Positive Sentiment: Olema reported better‑than‑expected quarterly results this week, which, along with raised analyst outlooks, is a near‑term bullish catalyst supporting the stock. Earnings Beat Drives Stock – AmericanBankingNews
• Positive Sentiment: Upcoming/preclinical data (palazestrant and OP‑3136) to be presented at AACR and a large reported $68.7M investor bet on a 2027 breast‑cancer launch are potential medium‑term catalysts for upside if data or investor interest validates the story. AACR Presentation – BusinessInsider Large Bet Report – The Globe and Mail
• Neutral Sentiment: Zacks notes the stock has been heavily sold (down ~33% over 4 weeks) and is technically oversold; that increases the chance of a short‑term bounce but also underscores elevated downside risk if catalysts disappoint. Oversold / Technical Note – Zacks
• Negative Sentiment: Guggenheim published a pessimistic forecast and an analyst downgrade hit headlines, pressuring the stock intraday — a reminder that not all desks are aligned with the recent bullish notes. Guggenheim Pessimistic Forecast – AmericanBankingNews
• Negative Sentiment: AmericanBankingNews reported an analyst downgrade that coincided with a notable intra‑day pullback, illustrating how mixed analyst views are fueling volatility. Analyst Downgrade / Price Reaction – AmericanBankingNews
• Negative Sentiment: Goldman Sachs trimmed its price target from $38 to $27 (while keeping a “Buy”), which reduces the consensus upside and may cap near‑term rallies until data or execution de‑risk the story. Goldman Lowers Target – Benzinga

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.